Atturos builds innovative biomarker-based diagnostic tests to support clinical decision making in prostate cancer. With its advanced protein biomarker discovery capability and MRM-based validation platform, Atturos has identified a panel of proteins predictive of extracapsular extension (ECE) in prostate cancer, which it is developing into a clinically validated test to ensure clinicians and patients make a more informed decision about treatment.